Hasil Pencarian - Mengran Cao

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling

    HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling oleh Yunjiang Zhou, Keke Wang, Yang Zhou, Tao Li, Mengdi Yang, Rui Wang, Yaxin Chen, Mengran Cao, Rong Hu

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    DPP9 regulates NQO1 and ROS to promote resistance to chemotherapy in liver cancer cells

    DPP9 regulates NQO1 and ROS to promote resistance to chemotherapy in liver cancer cells oleh Yunjiang Zhou, Yaxin Chen, Chenyuan Xuan, Xingyan Li, Yingying Tan, Mengdi Yang, Mengran Cao, Chi Chen, Xing Huang, Rong Hu

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth

    IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth oleh Mengdi Yang, Mengran Cao, Xin Zhang, Bin Fu, Yaxin Chen, Yingying Tan, Chenyuan Xuan, Yongren Su, Dashan Tan, Rong Hu

    Diterbitkan 2024-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Acquired temozolomide resistance in MGMTlow gliomas is associated with regulation of homologous recombination repair by ROCK2

    Acquired temozolomide resistance in MGMTlow gliomas is associated with regulation of homologous recombination repair by ROCK2 oleh Xin Zhang, Tao Li, Mengdi Yang, Qianming Du, Rui Wang, Bin Fu, Yingying Tan, Mengran Cao, Yaxin Chen, Qing Wang, Rong Hu

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

    Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study oleh Qi Li, Mengran Cao, Guosheng Yuan, Xiao Cheng, Mengya Zang, Ming Chen, Xiaoyun Hu, Jing Huang, Rong Li, Yabing Guo, Jian Ruan, Jinzhang Chen

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: